Clinical Trials Logo

Endometrial Neoplasms clinical trials

View clinical trials related to Endometrial Neoplasms.

Filter by:

NCT ID: NCT01979003 Completed - Endometrial Cancer Clinical Trials

Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion

Start date: September 2014
Phase: Early Phase 1
Study type: Interventional

To determine if Fluorescein systemic injection during hysterectomy procedure can be useful in revealing the depth of endometrial cancer invasion.

NCT ID: NCT01977274 Recruiting - Ovarian Cancer Clinical Trials

Predictive Clinical and Biological Parameters in Gynecological Cancer

GC-BIO
Start date: December 2013
Phase: N/A
Study type: Interventional

Research of predictive clinical and biological factors in breast cancer : genomic, proteomic, mutation

NCT ID: NCT01969396 Terminated - Clinical trials for Polycystic Ovary Syndrome

Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology

Start date: October 2013
Phase: N/A
Study type: Interventional

To assess the adequacy of an endometrial biopsy sample obtained using sonohysterography.

NCT ID: NCT01965080 Completed - Endometrial Cancer Clinical Trials

Exemestane in Advanced and Recurrent Endometrial Carcinoma

Start date: March 2004
Phase: Phase 2
Study type: Interventional

A phase II study of Exemestane in Advanced or recurrent endometrial carcinoma Hypothesis: Treatment With Exemestane can give a response rate of at least 30%

NCT ID: NCT01961102 Completed - Endometrial Cancer Clinical Trials

OSCAR ENDO One Stop Assessment of Risk for Endometrial Hyperplasia and Cancer

Start date: May 2013
Phase: N/A
Study type: Observational

It is to be achieved that in postmenopausal women through the combination of Hysteroscopy and intraoperative rapid section a positive predictive value (PPV) regarding the objective illness like endometrial cancer or adenomatous hyperplasia of 100% so as a negative predictive value (NPV) of 99%.

NCT ID: NCT01943058 Withdrawn - Clinical trials for Endometrial Adenocarcinoma

Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer

Start date: March 2014
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well megestrol acetate or levonorgestrel-releasing intrauterine system works in treating patients with atypical endometrial hyperplasia or endometrial cancer. Progesterone can cause the growth of endometrial cancer cells. Hormone therapy using megestrol acetate or levonorgestrel-releasing intrauterine system may fight endometrial cancer by lowering the amount of progesterone the body makes. It is not yet known whether megestrol acetate is more effective than levonorgestrel-releasing intrauterine system in treating atypical endometrial hyperplasia or endometrial cancer.

NCT ID: NCT01939028 Terminated - Clinical trials for Stage III Endometrial Carcinoma

Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery

Start date: July 2013
Phase: N/A
Study type: Interventional

This clinical trial studies lymph node mapping in patients with newly diagnosed endometrial cancer undergoing surgery. Lymph node mapping may help in planning surgery to remove endometrial cancer and affected lymph nodes.

NCT ID: NCT01935973 Completed - Clinical trials for Endometrial Adenocarcinoma

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Start date: September 30, 2013
Phase: Phase 1
Study type: Interventional

This randomized phase I trial studies how well trametinib with or without GSK 2141795 (protein kinase B [Akt] inhibitor GSK2141795) works in treating patients with endometrial cancer that has come back (recurrent) or does not go to remission despite treatment (persistent). Trametinib and Akt inhibitor GSK2141795 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trametinib is a more effective treatment for endometrial cancer when given with or without ATK inhibitor GSK2141795.

NCT ID: NCT01935934 Active, not recruiting - Clinical trials for Endometrial Serous Adenocarcinoma

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Start date: April 29, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well cabozantinib s-malate works in treating patients with endometrial cancer that has come back (recurrent) or has spread to other places in the body (metastatic). Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT01922778 Completed - Endometrial Cancer Clinical Trials

Screening for Endometrial Abnormalities in Overweight and Obese Women

Start date: September 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to develop an endometrial biopsy screening program for endometrial cancer and its precursor lesions in overweight and obese women. There is a BMI threshold at and above which optimal screening parameters exist for identifying endometrial cancer and its precursor lesions in overweight and/or obese women. Prevention, diagnosis and treatment of endometrial cancer and its precursor lesions in overweight and/or obese women offers substantial health benefits.